INTRODUCTION AND OBJECTIVES: Light-reflectance spectroscopy (LRS) is a novel technology which can reliably detect positive surgical margins (PSMs) for Gleason score 7 prostate cancer in ex vivo radical prostatectomy (RP) specimens. Furthermore, LRS can provide near-immediate feedback to the surgeon and potentially influence surgical decision making. Our objective was to refine our technique using a new algorithm to increase the efficacy and performance of this technology.
INTRODUCTION AND OBJECTIVES: Light-reflectance spectroscopy (LRS) is a novel technology which can reliably detect positive surgical margins (PSMs) for Gleason score 7 prostate cancer in ex vivo radical prostatectomy (RP) specimens. Furthermore, LRS can provide near-immediate feedback to the surgeon and potentially influence surgical decision making. Our objective was to refine our technique using a new algorithm to increase the efficacy and performance of this technology.
METHODS: A prospective evaluation of ex vivo RP specimens using LRS was performed at a single institution from March 2016 to October 2016. LRS measurements were performed on selected sites on the prostate capsule, marked with ink, and correlated with pathological analysis. The previous 5 feature algorithm, which has been validated using both a training and testing set, was further optimized with an additional 4 features. This new 9 feature algorithm included additional shifts in slope at specific points along the 690 nm -770 nm wavelength range to better differentiate malignant from benign tissue. The sensitivity, specificity, negative predictive value (NPV), positive predictive value (PPV), and area under the receiver operating characteristic curve (AUC) for LRS predicting PSMs using the 5 and 9 point algorithms were calculated.
RESULTS: 197 sites in 34 RP specimens were evaluated by LRS and histopathology. The 5 and 9 point algorithms behaved similarly for Gleason groups 1-2 showing poor sensitivity (33%,33%), PPV (18%,27%), and AUC (0.54,0.59). Specificity was better in the 9 compared to the 5 point algorithm (85.3 vs. 74.4%, respectively). Both algorithms performed much better for Gleason groups 3-4. Specificity was improved for the 9 point algorithm compared to the 5 (90.6 vs. 84.4%, respectively). Sensitivity was improved for the 5 point algorithm compared to the 9, (100 vs. 77.8%, respectively). Both algorithms had great NPV for low grade and high grade cancer.
CONCLUSIONS: Incorporating features of both LRS algorithms improves performance to reliably detect PSMs of higher grade prostate cancer. This is likely secondary to increased cellular density in these cancers causing more differential light scattering. Further refinements and additional prospective evaluations may allow incorporation into clinical practice.
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PD10-09 EFFECT OF DEHYDRATED HUMAN AMNION/CHORION MEMBRANE ALLOGRAFT ON URINARY CONTINENCE FOLLOWING ROBOT-ASSISTED RADICAL PROSTATECTOMY
Khaled Refaai, Hao Nguyen*, Ameli Niloufar, Wang Huiqing, Matthew Cooperberg, Peter Carroll, San Francisco, CA INTRODUCTION AND OBJECTIVES: Urinary incontinence following radical prostatectomy is one of the major concerns for both patients and surgeons. Efforts are being made to shorten the duration and degree of post-operative urinary incontinence, hence decreasing postoperative morbidity. Dehydrated Human Amnion/Chorion Membrane Allograft (AmnioFixâ) is a biodegradable material that may decrease postoperative nerve inflammation and improve postoperative outcomes (i.e. potency and continence). We aim to determine the effect of adding the dehydrated human amnion/chorion membrane allograft (Amniofixâ) on the neurovascular bundles on post-operative urinary incontinence in patients who underwent nerve sparing (complete bilateral, unilateral or partial) Robot-assisted Radical Prostatectomy (RARP).
METHODS: Retrospective review of 362 consented patients who underwent nerve sparing RARP between 2015-2016. AmnioFixâ usage, times to one and zero pads after catheter removal and type of nerve sparing were recorded. Cox proportional hazard modeling was used to evaluate the association between the use of AmnioFixâ and postoperative times to one and zero pads. RESULTS: Of the 362 patients analyzed, AmnioFixâ was used in 138 patients (38%). Mean age of the cohort was 63. Patients with AmnioFixâ allograft used reached the use of 1 (even occasional) and 0 pads at a mean of 1.28 months and 2.84 respectively, whereas those with no allograft had means of 1.61months and 3.20 months. In the allograft group, 64% of patients reached < 1 pads within 6 months of the RARP, compared to 48% in the no allograft group. In the model adjusted for PSA density, prostate weight, nerve sparing, age, race, and CAPRA risk, allograft use increased the likelihood of using < 1 pads within 12 months of RARP by 50% compared to those without the allograft (HR: 1.52, 95%CI: 1.10 to 2.10, p¼ 0.011). Men with complete nerve sparing were 44% more likely to report < 1 pads within 12 months of RARP compared to partial/unilateral nerve sparing (HR: 1.44, 59%CI: 0.996 to 2.09, p ¼0.052). Younger age was also an independent predictor of better continence following RARP. Study limitations include limited sample size and retrospective nature.
CONCLUSIONS: The use of dehydrated human amnion/ chorion membrane allograft at the time of RARP appears to improve time to complete continence and increase likelihood of using 1 and 0 pads within 12 months of surgery. Age and complete nerve sparing remain important determinant factors for continence. Our data warrant a prospective trial to evaluate the benefit of the anionic allograft. The gap in prostate cancer (PCa) survival between Blacks and Whites has widened over the past decade. Investigators hypothesize that this disparity may be partially attributable to differences in rates of definitive therapy between races. We therefore sought to examine the variation in use of definitive therapy among Black and White men for localized PCa.
METHODS: Using data from the National Cancer Data Base, we identified 283,135 White and Black men >¼40years of age with biopsy confirmed localized intermediate-high risk PCa diagnosed between January 2004 and December 2013. Multilevel logistic regression was fitted to predict the odds of receiving definitive therapy for PCa. Sensitivity and subgroup analyses were performed to adjust for inherent patient and facility-level differences.
RESULTS: 82.9% (n¼185,647) of White men received definitive therapy compared to 73.7% (n¼43,662) of Black men over a 10-year period. Overall rates of definitive therapy during that time increased for both White (81.3% vs. 83.3%, p<0.001) and Black (72.8% vs. 75.4%, p¼0.001) men. However, 38.5% of treating facilities demonstrated significantly higher rates of definitive therapy in White men, compared to just 0.8% of facilities favoring Black men.
CONCLUSIONS: After adjusting for sociodemographic and clinical factors, we found significant facility-level variation in rates of definitive therapy for intermediate-high risk localized PCa among White and Black men, with most facilities favoring therapy in Whites. Our study is limited by the retrospective nature of the cohort. Vol. 197, No. 4S, Supplement, Friday, May 12, 2017 THE JOURNAL OF UROLOGY â e203
